Technical Analysis for PALI - Palisade Bio, Inc.

Grade Last Price % Change Price Change
F 0.36 0.61% 0.00
PALI closed up 0.61 percent on Monday, March 18, 2024, on 3 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 21
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.61%
NR7 Range Contraction 0.61%
NR7-2 Range Contraction 0.61%
Narrow Range Bar Range Contraction 0.61%
New 52 Week Low Weakness 0.61%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 3% about 18 hours ago
Up 2% about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Palisade Bio, Inc. Description

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Surgery Abdominal Pain Digestive System Gastrointestinal Tract

Is PALI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.65
52 Week Low 0.3605
Average Volume 3,111,868
200-Day Moving Average 0.86
50-Day Moving Average 0.47
20-Day Moving Average 0.40
10-Day Moving Average 0.38
Average True Range 0.04
RSI (14) 37.11
ADX 9.78
+DI 20.78
-DI 22.90
Chandelier Exit (Long, 3 ATRs) 0.35
Chandelier Exit (Short, 3 ATRs) 0.47
Upper Bollinger Bands 0.44
Lower Bollinger Band 0.36
Percent B (%b) 0.09
BandWidth 20.92
MACD Line -0.03
MACD Signal Line -0.03
MACD Histogram 0.0009
Fundamentals Value
Market Cap 4.4 Million
Num Shares 12.1 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 1.13
Price-to-Sales 21.88
Price-to-Book 0.39
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.38
Resistance 3 (R3) 0.39 0.38 0.38
Resistance 2 (R2) 0.38 0.37 0.38 0.38
Resistance 1 (R1) 0.37 0.37 0.38 0.37 0.38
Pivot Point 0.37 0.37 0.37 0.37 0.37
Support 1 (S1) 0.36 0.36 0.36 0.36 0.35
Support 2 (S2) 0.35 0.36 0.35 0.35
Support 3 (S3) 0.34 0.35 0.35
Support 4 (S4) 0.34